On 22 April 2020, orphan designation EU/3/20/2265 was granted by the European Commission to Janssen-Cilag International N.V., Belgium, for cusatuzumab for the treatment of acute myeloid leukaemia.
|Disease / condition||
Treatment of acute myeloid leukaemia
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.